Vertex Finally Inks Orkambi Deal In England
Stalemate Over As Parties Agree Deal That Also Includes Symkevi And Kalydeco
Executive Summary
Vertex has finally managed to reach an agreement to bring its cystic fibrosis drugs Orkambi and Symkevi to patients in England, which constitutes an important slice of what is the second biggest market for the drugs.
You may also be interested in...
US Pharma Firms Not In Post-Brexit Trade Talks
A UK TV program revealed secret meetings between drug makers and British civil servants but for its part, the American Pharmaceutical Group says it has had no discussions on any future US/UK trade deal.
Vertex Versus NHS England: Was The Stand-Off Worth It?
After three years as the pharma bogeyman, Vertex has agreed a deal in England. So what purpose did the stand-off serve?
Vertex Strikes Spanish Payment-For-Results CF Deal
Vertex has struck a reimbursement deal in Spain for Orkambi and hopes that it will also make progress in England where a new proposal has been made by the company.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
